KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 139 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q3 2023. The put-call ratio across all filers is 1.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $430,689 | +11.2% | 24,795 | -9.9% | 0.00% | 0.0% |
| Q2 2023 | $387,468 | +21.1% | 27,519 | -7.5% | 0.00% | 0.0% |
| Q1 2023 | $320,056 | -29.2% | 29,745 | -1.4% | 0.00% | 0.0% |
| Q4 2022 | $451,947 | +31.0% | 30,170 | +12.4% | 0.00% | 0.0% |
| Q3 2022 | $345,000 | +25.0% | 26,851 | -5.8% | 0.00% | 0.0% |
| Q2 2022 | $276,000 | +31.4% | 28,503 | +35.1% | 0.00% | – |
| Q1 2022 | $210,000 | -77.2% | 21,100 | -57.5% | 0.00% | -100.0% |
| Q1 2021 | $920,000 | -3.8% | 49,700 | -8.1% | 0.00% | 0.0% |
| Q4 2020 | $956,000 | +19.9% | 54,100 | +4.0% | 0.00% | 0.0% |
| Q3 2020 | $797,000 | +36.7% | 52,000 | +127.1% | 0.00% | 0.0% |
| Q2 2020 | $583,000 | +75.1% | 22,900 | +6.5% | 0.00% | +100.0% |
| Q1 2020 | $333,000 | +42.3% | 21,500 | +24.3% | 0.00% | 0.0% |
| Q2 2019 | $234,000 | – | 17,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 2,474,561 | $42,983,125 | 5.17% |
| Rubric Capital Management LP | 3,077,449 | $53,455,289 | 2.00% |
| Parkman Healthcare Partners LLC | 509,810 | $8,855,400 | 1.62% |
| TANG CAPITAL MANAGEMENT LLC | 600,000 | $10,422,000 | 1.47% |
| AlphaCentric Advisors LLC | 110,000 | $1,910,700 | 1.08% |
| Lion Point Capital, LP | 130,691 | $2,270,103 | 1.01% |
| RICE HALL JAMES & ASSOCIATES, LLC | 650,366 | $11,296,857 | 0.72% |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 185,853 | $3,228,267 | 0.53% |
| ADVISORY RESEARCH INC | 204,098 | $3,545,182 | 0.49% |
| Jackson Creek Investment Advisors LLC | 65,607 | $1,140 | 0.48% |